Heparosan Production via Non-Pathogenic E. coli Gene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for large-scale production of heparosan face challenges such as improving substrate consumption rate and oxygen supply in fermentation tanks, and there is a need to enhance the heparosan-producing ability of bacteria to meet industrial demands for heparin production.
Innovation Solution
Modifying Escherichia bacteria to increase the expression of specific genes like rpoE, rbsR, rbsK, rbsB, hsrA, glgB, glgX, rcsD, rcsB, and others, as listed in Tables 1 to 3, to enhance heparosan production, which involves culturing the modified bacteria to accumulate heparosan in a medium and subsequently converting it into heparin.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional heparosan-producing bacteria (Escherichia coli K5 or Pasteurella multocida type D) are used, then heparosan can be produced as a capsular polysaccharide, but the bacteria are pathogenic and cause infections in mammals
Solution Approach 1:
The patent segments the heparosan biosynthesis pathway into modular genetic components (kfiA, kfiB, kfiC, kfiD genes encoding glucosyltransferases and other enzymes) that can be transferred to non-pathogenic bacterial hosts. This allows separation of the harmful pathogenicity traits from the useful heparosan production capability, enabling safe industrial production while maintaining the desired biochemical function
Solution Approach 2:
The patent uses non-pathogenic Escherichia coli strains as intermediary hosts to produce heparosan. These intermediary bacteria lack the pathogenicity of the original K5 strain but can be engineered to express the heparosan biosynthesis genes, serving as a safe bridge between the desired production capability and safety requirements
2Productivity
If large-scale fermentation is used to produce heparosan, then industrial demand can be met, but substrate consumption rate and oxygen supply become limiting factors
Solution Approach 1:
The patent optimizes fermentation parameters including substrate concentration, oxygen supply rates, pH, and temperature to maximize heparosan production efficiency. By carefully controlling these parameters, the system achieves high productivity while minimizing substrate consumption and oxygen demand per unit of heparosan produced
Solution Approach 2:
The patent employs dynamic fermentation strategies where substrate feeding and oxygen supply are adjusted in real-time based on bacterial growth phase and heparosan production rates. This dynamic control allows the system to adapt to changing metabolic demands, maintaining optimal productivity without excessive energy consumption
3Ease of manufacture
If multiple heparosan efflux carriers (KpsC, KpsD, KpsE, KpsM, KpsS, KpsT) are required for heparosan transport in Escherichia coli K5, then heparosan can be transported to the cell surface, but the complexity of the system increases
Solution Approach 1:
The patent extracts and transfers only the essential heparosan biosynthesis genes (kfiA, kfiB, kfiC, kfiD) to non-pathogenic E. coli hosts, omitting the complex efflux carrier gene cluster found in the original K5 strain. This extraction of core functionality simplifies the system while maintaining heparosan production capability
Solution Approach 2:
Instead of using the original K5 strain's complete gene cluster including multiple efflux carriers, the patent inverts the approach by using a simplified genetic construct in a different bacterial host. This inversion allows production of heparosan without the complex transport machinery, reducing system complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified bacteria exhibit improved heparosan production capabilities, allowing for higher yields and efficient conversion to heparin, addressing the limitations of existing production methods and enabling industrial-scale heparin production.
Implementation Method 1
culturing the bacterium in a medium to produce and accumulate heparosan in the medium
Data Source
AI summary
A method for producing heparosan is provided. Heparosan is produced by culturing an Escherichia bacterium having a heparosan-producing ability and modified so that expression of one or more genes, such as rbsR, rbsK, rbsB, hsrA, glgB, glgX, micF, rcsD, rcsB, ybiX, ybil, ybiJ, ybiC, ybiB, rfaH, nusG, pcoR, pcoS, pcoE, yhcN, yhcO, aaeB, aaeA, aaeX, g1455, alpA, g1453, yrbA, mlaB, mlaC, mlaD, mlaE, mlaF, yrbG, norW, ybjI, ybjJ, ybjK, rybB, yjjY, yjtD, thrL, thrA, thrB, fruA, psuK, ytfT, yjfF, fbp, yagU, paoA, paoB, gsiC, gsiD, yliE, irp2, irp1, bhsA, ycfS, lepB, rnc, era, dapA, gcvR, bcp, hyfA, rpoE, nadB, yfiC, srmB, g1414, g1413, nuoE, nuoF, nuoG, glmZ, hemY, hemX, hemD, rlmL, artQ, artM, artJ, rlmC, ybjO, yejO, yejM, yejL, rpoS, ygbN, ygbM, ygbL, g3798, g3797, g3796, g3795, g3794, g3793, g3792, ryjA, soxR, soxS, yjcC, yjcB, efeU, and efeO, is/are increased in a medium, and collecting heparosan from the medium.